CTSO - CytoSorbents Corp Stock Price, Fair Value and News

$1.02-0.02 (-1.92%)

Delayed as of 23 Oct 2024, 03:06 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CTSO Price Action

Last 7 days

-4.6%

Last 30 days

-32.9%

Last 90 days

3.0%

Trailing 12 Months

-44.1%

CTSO RSI Chart

CTSO Valuation

Market Cap

56.6M

Price/Earnings (Trailing)

-2.22

Price/Sales (Trailing)

1.52

EV/EBITDA

-2.58

Price/Free Cashflow

-2.67

CTSO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CTSO Fundamentals

CTSO Revenue

Revenue (TTM)

37.2M

Rev. Growth (Yr)

5.03%

Rev. Growth (Qtr)

1.11%

CTSO Earnings

Earnings (TTM)

-25.5M

Earnings Growth (Yr)

32.67%

Earnings Growth (Qtr)

34.83%

CTSO Profitability

EBT Margin

-70.89%

Return on Equity

-152.54%

Return on Assets

-47.78%

Free Cashflow Yield

-37.52%

CTSO Investor Care

Shares Dilution (1Y)

22.69%

Diluted EPS (TTM)

-0.53

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	36.7M	37.2M	0	0
2023	35.4M	36.4M	37.1M	36.3M
2022	41.3M	37.7M	36.1M	34.7M
2021	42.9M	45.1M	44.3M	43.2M
2020	28.5M	32.0M	36.5M	41.0M
2019	22.8M	23.2M	23.6M	24.9M
2018	17.0M	19.2M	21.1M	22.5M
2017	10.8M	12.2M	13.6M	15.2M
2016	5.9M	7.1M	8.2M	9.5M
2015	3.8M	3.7M	3.9M	4.8M
2014	3.1M	3.8M	4.1M	4.1M
2013	1.7M	1.9M	2.2M	2.4M
2012	366.9K	697.8K	1.0M	1.4M
2011	216.9K	126.5K	0	36.1K
2010	0	0	0	307.3K

Get all data in R, Python etc through our Historical Stock Data APIs

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CEO	Dr. Phillip P. Chan M.D., Ph.D.
WEBSITE	cytosorbents.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	198

CytoSorbents Corp Frequently Asked Questions

What is the ticker symbol for CytoSorbents Corp? What does CTSO stand for in stocks?

CTSO is the stock ticker symbol of CytoSorbents Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CytoSorbents Corp (CTSO)?

As of Tue Oct 22 2024, market cap of CytoSorbents Corp is 56.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTSO stock?

You can check CTSO's fair value in chart for subscribers.

Is CytoSorbents Corp a good stock to buy?

The fair value guage provides a quick view whether CTSO is over valued or under valued. Whether CytoSorbents Corp is cheap or expensive depends on the assumptions which impact CytoSorbents Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTSO.

What is CytoSorbents Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 22 2024, CTSO's PE ratio (Price to Earnings) is -2.22 and Price to Sales (PS) ratio is 1.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTSO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CytoSorbents Corp's stock?

In the past 10 years, CytoSorbents Corp has provided -0.166 (multiply by 100 for percentage) rate of return.